NCT03881345 Ongoing Registry of Treatment of Venous Thromboembolism
| NCT ID | NCT03881345 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medalp Private Surgery Clinic |
| Condition | Deep Vein Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2019-04-01 |
| Primary Completion | 2036-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2019-04-01 with a primary completion date of 2036-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ongoing registration of patients with venous thromboembolism treated by means of antithrombotic therapy, thrombolisys, open surgery, endovenous desobstruction and stenting.
Eligibility Criteria
Inclusion Criteria: * case of venous thrombosis of a limb or pulmonary embolus Exclusion Criteria: * no exclusion criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03881345 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Deep Vein Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03881345 currently recruiting?
Yes, NCT03881345 is actively recruiting participants. Contact the research team at evgeny@ilyukhin.info for enrollment information.
Where is the NCT03881345 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT03881345 clinical trial?
NCT03881345 is sponsored by Medalp Private Surgery Clinic. The trial plans to enroll 5,000 participants.